Published in

Elsevier, Thrombosis Research: Vascular Obstruction, Hemorrhage and Hemostasis, 6(131), p. e235-e239

DOI: 10.1016/j.thromres.2013.03.009

Links

Tools

Export citation

Search in Google Scholar

The prognostic value of pro-B-Type natriuretic peptide in acute pulmonary embolism.

Journal article published in 2013 by Franck Verschuren, Mathieu Bonnet, Marie-Odile Benoit, Damien Gruson, Francis Zech, Francis Couturaud ORCID, Nicolas Meneveau, Pierre-Marie Roy, Marc Righini, Guy Meyer, Olivier Sanchez
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

AIMS: To assess the clinical performance of pro-B-type natriuretic peptide 1-108 (proBNP) for the prognosis of acute pulmonary embolism. METHODS: This study was ancillary to a recently published multicentre study including 570 patients with acute pulmonary embolism. ProBNP values were analysed using a new sandwich immunoassay proBNP1-108, Bioplex2200 (Bio-Rade Laboratories). Data was compared with BNP and N-terminal (NT) proBNP values. Adverse outcomes at 30 days were defined as death, secondary cardiogenic shock, or recurrent venous thromboembolism. RESULTS: ProBNP values were analysed in 549 patients, with 39 (7.1%) presenting adverse outcomes. All three natriuretic peptides were significantly elevated in these 39 patients compared with the group without adverse outcomes (BNP: p